论文部分内容阅读
继2004年9月30日默克药厂同意撤除并回收市场销售的坏氧合酶(Cox)-2抑制剂罗非昔布(RofeCoxib,VIOXX)之后,美国食品药品管理局(FDA)于2004年12月9日又发出一个警告,辉瑞的Cox-2抑制剂伐地昔布(ValeCoxib),Bextra)有引发与心血管疾患相关的危险。特别是实施了冠状动脉搭桥手术以后使用伐地昔布,患者会出现血栓性疾病,如心肌梗死,卒中和肺栓塞等。另外,伐地昔布还可导致罕见的严重皮肤反应,如中毒性表皮坏死松解症、斯-约综合征和多形红斑。一周后,即2004年12月17日,FDA又宣布,由于超常的心血管疾病、心肌梗死和卒中发生,停止国家癌症研究所(NationalCancer Institute,NCI)尚未完成的塞来昔布预防腺瘤的研究(Adenoma Prevention with
Following the agreement on September 30, 2004 that Merck agreed to remove and recycle the commercially available Cox-2 inhibitor RofeCoxib (VIOXX), the U.S. Food and Drug Administration (FDA) On December 9, another warning was issued that Pfizer’s Cox-2 inhibitor Vale Coxib, Bextra, poses a risk of developing cardiovascular disease. In particular, the use of valdecoxib after coronary artery bypass graft surgery, patients with thrombotic diseases such as myocardial infarction, stroke and pulmonary embolism. In addition, valdecoxib can also cause rare severe skin reactions, such as toxic epidermal necrolysis, Sjogren Syndrome and erythema multiforme. A week later, on December 17, 2004, the FDA also announced that celecoxib, an unfinished product of the National Cancer Institute (NCI), had been discontinued due to abnormal cardiovascular disease, myocardial infarction, and stroke Study (Adenoma Prevention with